MAXIMIZATION OF DNA DAMAGE TO MGMT(+) EGFR(+) GBM CELLS USING OPTIMAL COMBINATION OF TEMOZOLOMIDE-ANTI EGFR MONOCLONAL ANTIBODY NIMOTUZUMAB by Andi Asadul Islam, Andi Asadul Islam
Bali Medical Journal (Bali Med J) 2015, Volume 4, Number 3: 109-113 
P-ISSN.2089-1180, E-ISSN.2302-2914 
Open access: www.balimedicaljournal.org and  www.ojs.unud.ac.id                                              109 
 
MAXIMIZATION OF DNA DAMAGE TO MGMT(+) EGFR(+) 
GBM CELLS USING OPTIMAL COMBINATION OF 
TEMOZOLOMIDE-ANTI EGFR MONOCLONAL ANTIBODY 
NIMOTUZUMAB 
 
1
Made Agus Mahendra Inggas, 
2
Eka J. Wahjoepramono, 
3
Sri Maliawan, 
4
Andi Asadul Islam 
 
1
Faculty of Medicine, Pelita Harapan University, Indonesia 
2
Mochtar Riady Comprehensive Cancer Center, Indonesia 
3
Faculty of Medicine, Udayana University, Bali-Indonesia 
4
Faculty of Medicine, Hasanudin University, Makasar-Indonesia 
 
Background: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor in 
adultswith dismal prognosis due to the unavailability of an effective therapy. Up to now, there had 
been no definitive studies published on EGFR inhibition therapy as a chemosensitizer for GBM 
therapy using Temozolomide (TMZ). This study aims to reveal the most effective method and timing 
to administer TMZ-anti EGFR targeted therapy which causes maximal DNA damage on GBM cells. 
Methods: Various regimens of anti EGFR monoclonal antibody Nimotuzumab (NMZ) was 
administered in different combinations with TMZ, performed on U87MG MGMT(+) EGFR(+) cells. 
The effectiveness of the combinations were evaluated by measuring yH2AX levels which reflects the 
degree of DNA damage. One-way Anova and LSD tests were performed to determine the effects of 
each treatment with p<0.05. Results and discussion: the mean SD of yH2AX of each treatment was: 
11,90±1,25 for the control group; 29.33±1.91 for NMZ alone; 28.13±1.58 for TMZ alone; 41.53±3.51 
for concurrent use; 35.67 ±2.65 for NMZ after 24 hours TMZ; 31.87±2.94 for NMZ after 48 hours 
TMZ; 39.57±4.2 for TMZ after 24 hours NMZ; and 35.93 ±3.56 for TMZ after 48 hours NMZ. The 
administration of TMZ concurrent with or after 24 hours NMZ gives the highest amount of DNA 
damage to GBM cells. Conclusion: The administration of Nimotuzumab targeted therapy up to 24 
hours before Temozolomide chemotherapy has been proven to be effective in maximizing the amount 
of DNA damage done to GBM cells in vitro.  
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INTRODUCTION 
Glioblastoma multiforme (GBM) is the most 
frequently found and most aggressive glial cell 
tumor, associated with a dismal prognosis and 
mean survival time of one year after diagnosis.
1,2
 
This poor prognosis is caused by our incomplete 
understanding on this aggressive tumor’s 
characteristics and the lack of an effective therapy.  
The standard chemotherapy agent for GBM is 
Temozolomide (TMZ).
3
 Many studies have been 
performed to overcome TMZ resistance, including 
modifications to administration dosage and 
mechanism, and the combination of TMZ with 
other agents or targeted therapies. Currently 
available targeted therapy for GBM include PI3-
K/mTOR, PDGFR, VEGF/angiogenesis, Hedgehog 
GLI1 and EGFR/ EGFRvIII.
4-7
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Overexpression and amplification of 
epidermal growth factor receptors (EGFR) is a 
dominant mutation of GBM cells, compared to 
other genetic mutations, and is linked to increased 
GBM cell resistance to radiotherapy and 
chemotherapy.
8
 Chen, et al in 2007 have identified 
the radioprotective function of EGFR, through 
intranuclear translocation and its interaction with 
DNA-dependent protein kinase (DNA-PK), a key 
component of non-homologous end-joining 
pathway in DNA repair.
9
 Even though Bao et al did 
not evaluate the pathways of DNA repair caused by 
induction of cytotoxic chemotherapy,
10
 an 
analogous mechanism may be at work here. By 
attempting to interrupt the DNA repair mechanisms 
of EGFR at an early stage, anti EGFR Monoclonal 
Antibody Nimotuzumab (NMZ) was given before 
TMZ therapy, in hope of achieving a synergistic 
effect as a model of TMZ therapy for GBM cells. 
This study hopes to discover the effect of 
combination TMZ-NMZ therapy to find out the 
most effective chemotherapy regiment for MGMT 
methylated (+) and EGFR overexpression (+) GBM 
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cells, especially in its DNA damage activity. 
Another goal for this study is to find the most 
effective administration order and interval. 
 
MATERIALS AND METHODS 
U87MG cell line culturing 
Expansion and maintenance of U87MG cells 
were done on the bottom surface of 150 cm2 TC 
flasks, submerged with 30 ml of growth medium. 
The growth medium consisted of Dulbeco’s 
Modified Eagle’s Medium (DMEM) [Gibco], 10% 
Fetal Bovine Albumin (FBS) [Invitrogen], 0.5% L-
Glutamine [Gibco], and 0,5% Gentamycin [Gibco]. 
After confluence some cells were transferred into 
new flasks for further expansion or experiment 
treatments. Some were added 10% Dimethyl 
Sulfoxide (DMSO) [Sigma] into its medium and 
frozen in cryovials submerged in liquid nitrogen as 
future usage stocks. Upon usage, DMSO were 
cleared off the cells by pelleting and replacing the 
medium as soon as it thawed. 
 
Drug dosage determination 
Cells were planted 3 days prior to 
Nimotuzumab (NMZ) and Temozolomide (TMZ) 
treatments, on 24-wells plate, submerged in growth 
medium. Each well was given 0, 10, 50, 100, 500, 
1000 ug/ml NMZ, and 0, 2, 10, 20, 100, 200 g/ml 
TMZ. Each treatment was done in duplet. Cells 
were observed under microscope every 24 hours for 
number and viability. 
After 24 hours, the other duplet had its 
medium aspirated dry, harvested by submerging 
with 0.1% trypsin [Gibco] for 5 minutes at 37C. 
Cells from each well then were suspended in 500 l 
PBS and analyzed by flow cytometry as separate 
samples: the whole 500 l PBS of each sample was 
run through flow cytometer and had its approximate 
total cell number recorded by the program. Optimal 
drug concentration was also determined by these 
cell numbers. 
 
U87MG drug treatment 
Cells were planted 3 days prior to 
Nimotuzumab (NMZ) and Temozolomide (TMZ) 
treatments, on 3x12-wells plates, submerged in 
growth medium. Then on the third day, cells were 
treated with 8 different treatments. 4 wells were 
allocated for each of these treatment groups: Non-
treated (Control), NMZ only for 72h (N), TMZ 
only for 72h (T), NMZ and TMZ for 72h (NT), 
NMZ after 24h TMZ (N24T), NMZ after 48h TMZ 
(N48T), TMZ after 24h NMZ (T24N), and TMZ 
after 48h NMZ (T48N). NMZ was given at 1000 
g/ml and TMZ at 20 g/ml in their respective 
treatment groups, both based optimal drug 
concentration determined beforehand. The rest 4 
wells were reserved as spare wells in case anything 
unexpected happened to any of the allocated wells 
prior to cell treatment, to ensure the cells within all 
wells to be treated were in possible best conditions 
and closest to identical numbers. Unused spare 
wells were later on used as flow-cytometry 
unlabeled control. 
 
U87MG flow cytometry 
After 72 hours of treatments, cells were 
harvested by submerging with 0.1% trypsin [Gibco] 
for 5 minutes at 37C. Every treatment group had 4 
wells available to stain with fluorescent tagged 
antibody. Each of these 4 wells was allocated to be 
stained with anti-yH2AX-APC [Cell Signaling] to 
analyze cell DNA damage of the samples.  
After trypsination, each well content was put 
into a single 1.7 ml microtube and washed once 
with staining buffer (PBS [Invitrogen] + 1% BSA 
[Sigma]) to remove the trypsin. Each tube which 
was allocated for anti-CD133-APC staining were 
directly resuspended with 50 ul staining buffer and 
added with 1 ul anti-CD133-APC and incubated for 
1 hour in a dark room at room temperature. 
All other samples were next fixated by 
resuspending them with 1% formaldehyde inside 
each micro-tube and incubate them all for 10 
minutes at 37
0
C, and then were washed with 
staining buffer to remove the formaldehyde. For the 
wells allocated for anti-yH2AX-APC, 
permeabilization of the outer plasma membrane and 
nuclear envelope was done by resuspending the cell 
pellet with 1% Triton-X [Biorad] in staining buffer 
and incubate them for 30 minutes at room 
temperature. Soon after permeabilization step, each 
of the samples were washed twice with staining 
buffer and then resuspended in 50 l staining buffer 
in their own respective microtubes. After that, each 
microtube was added with anti-yH2AX-APC. All 
tubes were incubated for 1 hour in a dark room at 
room temperature. 
After all treatment groups had been incubated 
for an hour, each tube was added with 450 ul of 
staining buffer, making each sample 500 ul in 
volume. Finally all samples were analyzed with 
flow cytometer [BD Accuri C6]. Samples with 
FITC fluorescent marker were excited by 488 nm 
blue laser and read at 533-563 nm wavelength 
channel, PE by 488 nm blue laser at 585-625 nm 
wavelength channel, and APC by 640 nm red laser 
at 675-700 nm wavelength channel. 
 
Statistical analysis 
Statistical analysis was performed using the 
SPSS for Windows, version 21.0. The significance 
of differences between groups was compared using 
One Way Anova. The significance of differences in 
groups was compared using LSD. Differences were 
considered significant if p < 0.05. 
 
RESULTS 
The results of flowcytometer examination of 
each treatment was presented in table and graph 
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form. Of each treatment group have 
CD133negative. yH2AX levels are significantly 
higher (p < 0.05) for all treatment protocols 
compared to the control group.  
 
Table 1 The Effects of NMZ, TMZ and Their 
Combinations to yH2AX Levels. 
Groups N 
yH2AX levels (%) 
Mean 
(SD) 
Difference in 
Mean from 
Control 
Control  3 11.90 
(1.25)
a 
0.00 
Nimotuzumab 
(NMT) 
3 29.33 
(1.91)
b 
17.43
p 
Temozolomide 
(TMZ) 
3 28.13 
(1.580
b 
16.23
p 
N and T 
combinations 
15 36,91 
(4.53)
c 
25.01
q 
Superscripted letters in the same column shows 
LSD results after One Way Anova test showing p > 
0.05; and its significant difference p < 0.05. The 
group with combination therapy resulted in 
significantly higher yH2AX levels when compared 
to the mono-therapy groups. There are no 
significant differences between single therapy NMT 
or TMZ groups.  
 
Data of yH2AX levels grouped by order of 
and interval of drug administration were presented 
in Table 2. 
Table 2 
 yH2AX levels grouped by order of and interval of 
drug administration 
Groups 
yH2AX levels (%) 
Mean (SD) 
Different in 
mean from 
control group 
Control (C) 11.90 (1.25)
a 
0.00 
NMZ after 48 
hours TMZ 
(N48T) 
31.87 (2.94)
b 
19.97
p 
TMZ after 48 
hours NMZ 
(T48N) 
35.93 (3.56)
c 
24.03
q 
NMZ after 24 
hours TMZ 
(N24T) 
35.67 (2.65)
c 
23.77
q 
TMZ after 24 
hours NMZ 
(T24N) 
39.56 (2.06)
d 
27.66
r 
Concurrent 
TMZ and NMZ 
use 
41.53 (3.51)
d 
29.63
r 
Superscripted letters in the same column shows 
LSD results after One Way Anova test showing p > 
0.05; and its significant difference p < 0.05. 
Table 2 shows the results of various 
combinations of NMZ and TMZ therapy, by order 
and treatment interval. The mean yH2AX levels in 
the combined NMZ and TMZ groups vary 
depending on their administration order and 
administration interval. The highest yH2AX levels 
are found in the concurrent therapy group (mean 
41.53±3.51), and lowest in the NMZ after 48 hours 
TMZ group (mean 31.87±2.94). The differences are 
significant between the concurrent therapy group 
and the N24T, N48T and T48N groups; but not 
significant between the concurrent group and the 
T24N group.  
 
DISCUSSION 
Repair of DNA damage in GBM cells 
This is a pioneer study in investigating the 
effect of the administering Nimotuzumab/NMZ (N) 
on the effectiveness of Temozolomide/TMZ (T), 
assessing the effects of the order of administration 
and the interval between administrations on the 
degree of DNA damage as represented by yH2AX 
levels. Higher yH2AX levels are interpreted as a 
higher degree of DNA damage. The highest 
significant yH2AX levels were identified when 
Temozolomide and Nimotuzumab were given 
concurrently, or when Temozolomide was given 
after 24 hours Nimotuzumab; compared to the 
yH2AX level in the control group. yH2AX levels 
increase by degrees between the T, N, N48T, 
N24T, T48N, T24N and NT groups. The combined 
use of Temozolomide and Nimotuzumab is proven 
to increase the degree of DNA damage 
significantly, when compared to the control group 
and monotherapy groups. 
The repair of double-stranded DNA damage 
(DNA double strain breaks, DNA DSBs) is achieved 
through two pathways. The first pathway is to 
combine a sequence of DNA with a homologous 
template (homologous recombinant, HR), and the 
second pathway is to combine the end sequence of 
damaged DNA based on the presence of proteins 
and sequential systems (non homologous-end 
joining, NHEJ). NHEJ is the dominant pathway in 
repairing DNA DSBs, with the HR pathway as a 
supporting pathway.
9
 The NHEJ pathway is active 
during the cell cycle, and occurs mostly at the G1 
phase; the HR pathway happens after DNA 
replication was performed, where identical 
chromatins are used as a template in the repair 
process.
11
  
In the NHEJ pathway, recombination the 
damaged DNA chains depend on the activity of sub 
unit Ku70 dan Ku80, which is the main mechanism 
for DNA recombination. They are tied to the DNA 
end chains, which activates the catalytic subunit of 
DNA protein kinase (DNA-PK) and Artemis, which 
interacts with the proteins between the DNA-PK 
molecules and forms a bridge between the DNA 
end chains. The combination of DNA-PK and 
Artemis becomes phosphorylated and activates 
other enzymes, such as Ligase IV/XRCC4 and 
polynucleotide kinase (PNK). Outside of the 
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aforementioned process, protein complexes Mre11, 
Rad 50, and Nbs1(MRN) are also able to recombine 
and repair DNA fragments. Therefore, the DNA-
PK enzyme plays a key role in repairing DNA 
DSBs.
12
 EGFR also is one of themain keysin 
inhibiting of DNA DSBs repair.
9
 In NHEJ pathway, 
interactions of EGFRwith DNA-PKwill control the 
disassembly of DNA-PK and the physical rejoining 
of DNA DSBs. EGFRbinds to the catalytic sub unit 
of DNA-PK and controls regulatory subunits Ku70 
of DNA-PK.
15
 By block of EGFR translocation into 
the nucleoplasm, the interactions of EGFR-DNA 
PK will interupted.
13,14
  
 
Optimal Combination for DNA Damage 
The LSD statistical test was performed to 
investigate the difference between the order of 
administration and the interval between the 
administration of Nimotuzumab and 
Temozolomide, and it shows that concurrent 
administration is significantly better than other drug 
regiments, except the administration of 
Nimotuzumab within 24 hours before the 
administration of Temozolomide. This proves that 
giving Nimotuzumab before Temozolomide can 
increase the degree of DNA damage caused by 
Temozolomide. This effect is thought to be caused 
by the effects of Nimotuzumab in inhibiting 
intracellular translocation of EGFR, and inhibiting 
the effect of DNA repair enzymes (DNA-PK) in 
repairing DNA double strain breaks.
13 
Similar drug administration order, with 
different administration interval, was shown to have 
a different effect; T24N has higher yH2AX levels 
than T48N, and N24T has higher yH2AX levels 
than N48T. This indicates that the timing of 
administration has an effect on the increased DNA 
damage mechanism. This study shows that the 
administration of Temozolomide or Nimotuzumab 
within 24 hours before the next drug can increase 
DNA damage compared to 48 hours. This is 
thought to be caused by a very fast reaction phase 
by the defensive mechanism of GBM cells towards 
radiochemotherapy; within 1-4 hours of drug 
administration, intranuclear EGFR translocation 
and DNA-PK already begins to repair the DNA 
damage caused by Temozolomide.
9
 The 
administration of Nimotuzumab within the first 24 
hours is effective in inhibiting the DNA repair 
process, while Temozolomide continues to cause 
DNA damage and DNA double strain breaks.
16
 The 
administration of Nimotuzumab in the first 24 
hours will inhibit the interaction and activity of 
EGFR-DNA-PK enzyme, increasing DNA damage 
in vitro. The inhibition of DNA repair through the 
main NHEJ pathways by EGFR-DNA PK 
interaction will increase the ability of 
Temozolomide in causing damage to GBM cell 
DNA.  
 
 
CONCLUSION 
The administration of Nimotuzumab, 
concurrently or within 24 hours before the 
administration of Temozolomide, is an effective 
combination in maximizing DNA damage to the 
DNA of GBM cells in vitro.  The initial inhibition 
of DNA repair enzymes (DNA PK) through the 
mechanism of EGFR blockage will synergize with 
the effects of Temozolomide in causing DNA 
damage. 
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